Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Kay H"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Mol Omics
Histone deacetylase (HDAC) proteins, which regulate the acetylation state of proteins, are the targets of multiple clinical drugs for cancer treatment. Due to the heterogeneity of tumors, HDAC proteins play different roles in the progression of vario
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bb1763481e1e5800fb51aa54fa8bf83
https://europepmc.org/articles/PMC8355046/
https://europepmc.org/articles/PMC8355046/
Autor:
Abdulateef Alqahtani, Ayad A. Al-Hamashi, Matthew Dunworth, Joseph R. Knoff, Robert A. Casero, Mary Kay H. Pflum, Lalith Perera, Endri Karaj, L. M. Viranga Tillekeratne, Radhika Koranne, Maisha S. Rashid, Samkeliso Dlamini, William R. Taylor
Publikováno v:
Bioorg Chem
Despite the advances in treatment strategies, cancer is still the second leading cause of death in the USA. A majority of the currently used cancer drugs have limitations in their clinical use due to poor selectivity, toxic side effects and multiple
Autor:
Nuwan P. N. Acharige, Mary Kay H. Pflum, Hongbo Ling, Edward Seto, Irene Santos-Barriopedro, Sonali Bahl
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 12, Iss 5, Pp 1-17 (2021)
Cell Death and Disease, Vol 12, Iss 5, Pp 1-17 (2021)
HDAC1 is the prototypical human histone deacetylase (HDAC) enzyme responsible for catalyzing the removal of acetyl group from lysine residues on many substrate proteins. By deacetylating histones and non-histone proteins, HDAC1 has a profound effect
Publikováno v:
European Journal of Medicinal Chemistry. 143:1790-1806
Histone deacetylase (HDAC) enzymes govern the post-translational acetylation state of lysine residues on protein substrates, leading to regulatory changes in cell function. Due to their role in cancers, HDAC proteins have emerged as promising targets
Autor:
Mary Kay H. Pflum, Ahmed T. Negmeldin
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:3254-3258
Histone deacetylase (HDAC) proteins have emerged as important targets for anti-cancer drugs, with four small molecules approved for use in the clinic. Suberoylanilide hydroxamic acid (Vorinostat, SAHA) was the first FDA-approved HDAC inhibitor for ca
Publikováno v:
ACS Medicinal Chemistry Letters. 8:281-286
Histone deacetylase (HDAC) proteins are epigenetic regulators that deacetylate protein substrates, leading to subsequent changes in cell function. HDAC proteins are implicated in cancers, and several HDAC inhibitors have been approved by the FDA as a
Autor:
Ahmed T. Negmeldin, Christin L. Hanigan, L. M. Viranga Tillekeratne, Robert A. Casero, Jehad Almaliti, Ayad A. Al-Hamashi, Mary Kay H. Pflum, Lalith Perera
Publikováno v:
Journal of Medicinal Chemistry. 59:10642-10660
A number of analogues of the marine-derived histone deacetylase inhibitor largazole incorporating major structural changes in the depsipeptide ring were synthesized. Replacing the thiazole-thiazoline fragment of largazole with a bipyridine group gave
Autor:
Radhika Koranne, Mary Kay H. Pflum, Joseph R. Knoff, Samkeliso Dlamini, L. M. Viranga Tillekeratne, Ahmed T. Negmeldin, William R. Taylor, Ayad A. Al-Hamashi
Publikováno v:
Proceedings, Vol 22, Iss 1, p 63 (2019)
Epigenetic regulation of gene expression without changing DNA sequences is a promising strategy in developing therapeutic agents for human diseases, especially cancer. Histone deacetylases (HDACs) are a family of enzymes involved in epigenetic modula